Abstracts tagged "Comorbidity"

Abstract Number: 1855 • 2012 ACR/ARHP Annual Meeting
Prevalence of Potential Drug-Drug and Drug-Condition Interactions in Fibromyalgia Patients Newly-Initiating Pregabalin or Duloxetine
Stephen Johnston¹, Margarita Udall², Joseph C. Cappelleri³, Barbara H. Johnson⁴, George Shrady⁴ and Stuart L. Silverman⁵, ¹Truven Health Analytics, Bethesda, MD, ²Pfizer Inc., New York, NY, ³Pfizer Inc., Groton, CT, ⁴Truven Health Analytics, Washington, DC, ⁵Cedars-Sinai Medical Center, UCLA Center of Excellence, Los Angeles, CA
Background/Purpose: Drug-drug and drug-condition interactions (DDI/DCI) can present a significant challenge to the appropriate prescribing of drugs. The risk of DDI/DCI may be elevated in…
Abstract Number: 1814 • 2012 ACR/ARHP Annual Meeting
Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
Michael A. Becker¹, Xiangyang Ye², Kasem S. Akhras³, Rima H. Tawk⁴, Sudhir Unni², Jason Young² and Carl V. Asche⁵, ¹Medicine, University of Chicago, Chicago, IL, ²University of Utah College of Pharmacy, Salt Lake City, UT, ³Global Outcomes Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, ⁴Center for pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, ⁵Center for Outcomes Research, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Gout is a common acute and potentially progressive disease affecting approximately 8 million Americans. Hyperuricemia (serum urate levels [sUA] >6.8mg/dL) is a major pathogenic…
Abstract Number: 1225 • 2012 ACR/ARHP Annual Meeting
Self Reported Comorbidity Is Common in Early Inflammatory Arthritis and Associated with Poorer Function and Quality of Life and Greater Disease Activity: Results From the Canadian Early Arthritis Cohort
Carol A. Hitchon¹, Gilles Boire², Boulos Haraoui³, Edward Keystone⁴, Janet E. Pope⁵, Vivian P. Bykerk⁶ and Canadian Early Arthritis Cohort (CATCH) Investigators⁷, ¹University of Manitoba, Winnipeg, MB, Canada, ²Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Toronto, Canada
Background/Purpose: Chronic comorbid medical conditions may contribute to poor outcomes in rheumatoid arthritis. The extent of comorbidity, in particular cardiovascular disease (CVD), may be related…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].